Latest News and Press Releases

ZUG, Switzerland, Feb. 2, 2017 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...

ZUG, Switzerland, Jan. 26, 2017 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs...

TACTT3 Phase 3 trial to resume enrollment in early 2017 as previously announced ZUG, Switzerland, Dec. 6, 2016 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage...

AM-111 Phase 3 program for acute inner ear hearing loss is ongoing Amended TACTT3 trial of KeyzilenTM provides clear path forward for acute inner ear tinnitus program Conference call today...

Zug, Switzerland, Nov. 3, 2016 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology,...

TACTT3 Phase 3 trial protocol amended based on analysis of TACTT2 trial outcomes TACTT3 enrollment to be expanded with top-line results expected in early 2018 Conference call scheduled for...

Zug, Switzerland, October 10, 2016 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...

Presentation of safety data from KeyzilenTM program and symposium on tinnitus pharmacotherapy set for September 18 and 19 ZUG, Switzerland, September 13, 2016 -- Auris Medical Holding AG...

ZUG, Switzerland, September 9, 2016 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...

TACTT2 trial with KeyzilenTM for acute inner ear tinnitus did not meet efficacy endpoints Top-line results from TACTT3 trial with KeyzilenTM expected in the fourth quarter of 2016 AM-111 Phase...